- Presentation of clinical data from a pneumonia study on multi-pathogen infections at ICAAC 2014 and DGHM 2014
- Rapid Multiplex PCR assays confirmed as valuable addition to conventional testing methods
Curetis AG, a developer of next-level molecular diagnostic solutions, today announced new data on the clinical performance of its Unyvero P50 pneumonia cartridge in multi-pathogen infections.
A study conducted by researchers from private laboratory medicine firm MVZ Dr. Eberhard & Partner (Dortmund, Germany) analyzed pneumonia patient samples with both Curetis’ Unyvero P50 pneumonia cartridge and with classical microbiology culture. The investigator-initiated study determined >80% sensitivity at >95% specificity for pathogen identification with Unyvero P50. Of note, 54% of all cases had polymicrobial infections, many of them involving between 3 and 6 different pathogens. In the trial, Unyvero P50 found additional polymicrobial infections and detected 17 pathogens, all of which were not identified by microbiology culture. In contrast, in 6 cases classical culture identified a total of 8 pathogens not detected by Unyvero P50.